Skip to search formSkip to main contentSkip to account menu

UCB 34714

Known as: UCB-34714, UCB34714 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Brivaracetam

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Schedules of Controlled Substances: Placement of Brivaracetam Into Schedule V. Final rule.
This final rule adopts without change an interim final rule with request for comments published in the Federal Register on May 12… 
2016
2016
Schedules of Controlled Substances: Placement of Brivaracetam Into Schedule V. Interim final rule, with request for comments.
The Drug Enforcement Administration is placing the substance brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide… 
Review
2007
Review
2007
Brivaracetam (UCB 34714).
Brivaracetam (UCB 34714) is chemically related to levetiracetam (LEV, Keppra). It possesses a binding affinity for the synaptic… 
Review
2006
Review
2006
New antiepileptic drugs that are second generation to existing antiepileptic drugs
In the last decade, 10 new antiepileptic drugs (AEDs) have been introduced that offer appreciable advantages in terms of their… 
Review
2005
Review
2005
Brivaracetam UCB.
Brivaracetam (UCB-34714), an orally active, high-affinity synaptic vesicle protein 2A ligand, is being developed by UCB for the… 
2004
2004
UCB 34714: effect on inhibitory and excitatory neurotransmission
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)